TILRAY BRANDS INC (TLRY)
US88688T1007 - Common Stock
We assign a fundamental rating of 3 out of 10 to TLRY. TLRY was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TLRY have multiple concerns. While showing a medium growth rate, TLRY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TLRY had negative earnings in the past year.
In the past year TLRY has reported a negative cash flow from operations.
In the past 5 years TLRY always reported negative net income.
TLRY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of TLRY (-8.35%) is better than 74.36% of its industry peers.
Looking at the Return On Equity, with a value of -10.48%, TLRY is in the better half of the industry, outperforming 79.49% of the companies in the same industry.
TLRY's Return On Invested Capital of 1.55% is fine compared to the rest of the industry. TLRY outperforms 78.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.35% | ||
| ROE | -10.48% | ||
| ROIC | 1.55% |
ROA(3y)-23.71%
ROA(5y)-23.46%
ROE(3y)-42.39%
ROE(5y)-54.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TLRY has a Operating Margin of 10.30%. This is amongst the best in the industry. TLRY outperforms 83.59% of its industry peers.
TLRY has a Gross Margin of 28.01%. This is comparable to the rest of the industry: TLRY outperforms 51.79% of its industry peers.
TLRY's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.3% | ||
| PM (TTM) | N/A | ||
| GM | 28.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-15.87%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TLRY is destroying value.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
TLRY has more shares outstanding than it did 5 years ago.
TLRY has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.40, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
TLRY has a Altman-Z score (0.40) which is comparable to the rest of the industry.
TLRY has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TLRY (0.11) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.4 |
ROIC/WACC0.2
WACC7.92%
2.3 Liquidity
TLRY has a Current Ratio of 1.92. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of TLRY (1.92) is worse than 66.67% of its industry peers.
TLRY has a Quick Ratio of 1.18. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY has a worse Quick ratio (1.18) than 75.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 87.83% over the past year.
The Revenue has grown by 24.66% in the past year. This is a very strong growth!
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.21% yearly.
EPS 1Y (TTM)87.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q93.68%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y55.43%
Revenue growth 5Y98.21%
Revenue growth Q2Q29.35%
3.2 Future
Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.33% on average per year.
TLRY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.94% yearly.
EPS Next Y90.13%
EPS Next 2Y39.84%
EPS Next 3Y25.27%
EPS Next 5Y15.33%
Revenue Next Year33.01%
Revenue Next 2Y21.64%
Revenue Next 3Y18.07%
Revenue Next 5Y17.94%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TLRY indicates a rather cheap valuation: TLRY is cheaper than 92.31% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.46 |
4.3 Compensation for Growth
TLRY's earnings are expected to grow with 25.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.84%
EPS Next 3Y25.27%
5. Dividend
5.1 Amount
No dividends for TLRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TILRAY BRANDS INC
NASDAQ:TLRY (4/26/2024, 7:19:52 PM)
After market: 1.8 +0.02 (+1.12%)1.78
+0.03 (+1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.38B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.35% | ||
| ROE | -10.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 10.3% | ||
| PM (TTM) | N/A | ||
| GM | 28.01% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)87.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y90.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)24.66%
Revenue growth 3Y55.43%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y